Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2021 | Antibiotics impact outcomes with pembrolizumab in NSCLC patients

David Pinato, MD, MRes, PhD, Imperial College London, London, UK, outlines the impact of host determinants on response to immunotherapy in patients with non-small cell lung cancer (NSCLC), highlighting PD-L1 expression as a biomarker for pembrolizumab response. Dr Pinato also discusses the findings of a study which reported that antibiotic therapy has a significant negative impact on pembrolizumab monotherapy outcomes, but not on chemotherapy outcomes, in patients with NSCLC. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

David Pinato, MD, MRes, PhD, has received lecture fees from ViiV Healthcare and Bayer Healthcare; has received travel expenses from BMS and Bayer Healthcare; has received consulting fees from Mina Therapeutics, EISAI, Roche and Astra Zeneca; and has received research funding (to the institution) from MSD and BMS.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.